PROVO, Utah--(BUSINESS WIRE)--GeNOsys, Inc. (OTCBB: GNYS) today announced that they have entered into a consulting agreement with Inosol Co. LLC. to prepare the Company’s nitric oxide generator for commercial production. Commercial production is expected following the completion of the Company Federal Drug Administration (“FDA”) required procedures. Inosol is owned and managed by Mr. Stephen Fairbanks. Mr. Fairbanks has more than twenty years of experience in the design and manufacture of medical equipment used to administer and/or monitor medical gas to patients. Mr. Fairbanks was involved with the team that designed and received FDA approval for the first transport device used to monitor nitric oxide administration to a patient.
